These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 15003452

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Implications of PDE4 structure on inhibitor selectivity across PDE families.
    Ke H.
    Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
    Kelly JJ, Barnes PJ, Giembycz MA.
    Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
    [Abstract] [Full Text] [Related]

  • 6. Mapping the functional domains of human recombinant phosphodiesterase 4A: structural requirements for catalytic activity and rolipram binding.
    Jacobitz S, McLaughlin MM, Livi GP, Burman M, Torphy TJ.
    Mol Pharmacol; 1996 Oct; 50(4):891-9. PubMed ID: 8863835
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Crystal structure of phosphodiesterase 4D and inhibitor complex(1).
    Lee ME, Markowitz J, Lee JO, Lee H.
    FEBS Lett; 2002 Oct 23; 530(1-3):53-8. PubMed ID: 12387865
    [Abstract] [Full Text] [Related]

  • 9. Detailed characterization of a purified type 4 phosphodiesterase, HSPDE4B2B: differentiation of high- and low-affinity (R)-rolipram binding.
    Rocque WJ, Holmes WD, Patel IR, Dougherty RW, Ittoop O, Overton L, Hoffman CR, Wisely GB, Willard DH, Luther MA.
    Protein Expr Purif; 1997 Mar 23; 9(2):191-202. PubMed ID: 9056484
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Investigation of the relationship between protein-protein interaction and catalytic activity of a heme-regulated phosphodiesterase from Escherichia coli (Ec DOS) by protein microarray.
    Sasakura Y, Kanda K, Yoshimura-Suzuki T, Matsui T, Fukuzono S, Shimizu T.
    Biochemistry; 2005 Jul 19; 44(28):9598-605. PubMed ID: 16008345
    [Abstract] [Full Text] [Related]

  • 13. Partial characterization of the active site human platelet cAMP phosphodiesterase, PDE3A, by site-directed mutagenesis.
    Cheung PP, Yu L, Zhang H, Colman RW.
    Arch Biochem Biophys; 1998 Dec 01; 360(1):99-104. PubMed ID: 9826434
    [Abstract] [Full Text] [Related]

  • 14. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
    Richter W, Unciuleac L, Hermsdorf T, Kronbach T, Dettmer D.
    Cell Signal; 2001 Apr 01; 13(4):287-97. PubMed ID: 11306246
    [Abstract] [Full Text] [Related]

  • 15. The crystal structure of AMP-bound PDE4 suggests a mechanism for phosphodiesterase catalysis.
    Huai Q, Colicelli J, Ke H.
    Biochemistry; 2003 Nov 18; 42(45):13220-6. PubMed ID: 14609333
    [Abstract] [Full Text] [Related]

  • 16. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
    Zhu B, Kelly J, Vemavarapu L, Thompson WJ, Strada SJ.
    Biochem Pharmacol; 2004 Aug 01; 68(3):479-91. PubMed ID: 15242814
    [Abstract] [Full Text] [Related]

  • 17. PDE4B5, a novel, super-short, brain-specific cAMP phosphodiesterase-4 variant whose isoform-specifying N-terminal region is identical to that of cAMP phosphodiesterase-4D6 (PDE4D6).
    Cheung YF, Kan Z, Garrett-Engele P, Gall I, Murdoch H, Baillie GS, Camargo LM, Johnson JM, Houslay MD, Castle JC.
    J Pharmacol Exp Ther; 2007 Aug 01; 322(2):600-9. PubMed ID: 17519386
    [Abstract] [Full Text] [Related]

  • 18. Dual inhibition of human type 4 phosphodiesterase isostates by (R, R)-(+/-)-methyl 3-acetyl-4-[3-(cyclopentyloxy)-4-methoxyphenyl]-3- methyl-1-pyrrolidinecarboxylate.
    Tian G, Rocque WJ, Wiseman JS, Thompson IZ, Holmes WD, Domanico PL, Stafford JA, Feldman PL, Luther MA.
    Biochemistry; 1998 May 12; 37(19):6894-904. PubMed ID: 9578576
    [Abstract] [Full Text] [Related]

  • 19. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
    Kapui Z, Bence J, Boronkay E, Mikus E, Urbán Szabó K, Baranyi A, Arányi P.
    Neurobiology (Bp); 1999 May 12; 7(1):71-3. PubMed ID: 10746252
    [No Abstract] [Full Text] [Related]

  • 20. TcPDE4, a novel membrane-associated cAMP-specific phosphodiesterase from Trypanosoma cruzi.
    Alonso GD, Schoijet AC, Torres HN, Flawiá MM.
    Mol Biochem Parasitol; 2006 Jan 12; 145(1):40-9. PubMed ID: 16225937
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.